Program
Human Growth Hormone
Also written as “somatropin”, “Somatropin” and “PEG-somatropin”.
Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome · Dwarfism · Growth Disorders · Genetic Diseases, Inborn, led by 15 companies.
Drug pageHuman Growth Hormone: every studyMany companies study it; this page follows only the 117 they lead. All 217 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 340 open or running | phase 4since Sep 13, 2005 | Feb 1, 2005 | none ahead |
| Changchun GeneScience Pharmaceuticalits history only | 194 open or running | phase 4since Nov 27, 2014 | Apr 21, 2011 | Apr 28, 2027phase 4 · NCT07691125 |
| Merck KGaA, Darmstadt, Germanyits history only | 190 open or running | phase 4since Nov 18, 2005 | May 13, 2004 | none ahead |
| Pfizerits history only | 180 open or running | phase 4since Feb 5, 2007 | Sep 9, 2005 | none ahead |
| Eli Lillyits history only | 100 open or running | phase 4since Dec 15, 2005 | Sep 12, 2005 | none ahead |
| LG Chem | 40 open or running | phase 4since Nov 10, 2016 | Dec 29, 2005 | none ahead |
| Daewoong Pharmaceuticalits history only | 20 open or running | phase 3since Jan 19, 2016 | Sep 23, 2011 | none ahead |
| Ferring Pharmaceuticalsits history only | 20 open or running | phase 3since Nov 7, 2005 | Nov 7, 2005 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 4since Dec 4, 2014 | Mar 11, 2004 | none ahead |
| Ipsenits history only | 20 open or running | phase 4since Aug 24, 2011 | Oct 5, 2005 | none ahead |
| Altus Pharmaceuticalsits history only | 10 open or running | phase 2since Feb 2, 2009 | Feb 2, 2009 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Nov 28, 2011 | Nov 28, 2011 | none ahead |
| Clinique Ovoits history only | 10 open or running | phase 4since Oct 24, 2012 | Oct 24, 2012 | none ahead |
| Sanofiits history only | 10 open or running | phase 3since Mar 23, 2007 | Mar 23, 2007 | none ahead |
| Zhongshan Sansure Hygene Biomedicineits history only | 11 open or running | phase 3since Sep 2, 2026 | Sep 2, 2026 | Oct 2028phase 3 · NCT07815626 |
Also a collaborator on its studies: Merck Serono S.A.S, France, Merck Serono Co., Ltd., China, Merck Serono S.P.A., Italy, Merck Serono S.A., Geneva, Merck, S.L., Spain and BioPartners.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of LG Chem only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 29, 2005First study: phase 3 study in Dwarfism, PituitaryFirst studyNCT00271518 · 144 enrolled · United States
- Feb 20, 2006Phase 3 study in Pituitary DiseasesNCT00294619 · 147 enrolled · United States
- Nov 10, 2016Phase 4 study in DwarfismNCT03015909 · 116 enrolled · Korea, Republic of
- Sep 9, 2019Phase 1 study in Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy VolunteersNCT04085224 · 24 enrolled · Korea, Republic of
- Jul 28, 2021Named human growth hormoneINNProposed as its International Nonproprietary Name in WHO's List 125
TargetBeta
“Growth hormone receptor agonist”ChEMBL 37, by rule
Other programs on GHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lonapegsomatropinrule | ascendis-pharma-endocrinology-division-a-s | phase 3 | 6 |
Studies
All 4 LG Chem leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04085224Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy Volunteers · Korea, Republic of | 1 | Completed | Jan 2, 2020 | 24 |
| NCT03015909Dwarfism · Korea, Republic of | 4 | Completed | Dec 21, 2017 | 116 |
| NCT00294619Pituitary Diseases · United States | 3 | Completed | Mar 2008 | 147 |
| NCT00271518Dwarfism, Pituitary · United States | 3 | UNKNOWN | Dec 2013 | 144 |
How it is read
Names in the registry
- “somatropin”, 52 entries
- “Somatropin”, 27 entries
- “PEG-somatropin”, 13 entries
- “Saizen®”, 6 entries
- “Genotropin”, 5 entries
Conditions, from the studies’ own filings
- Dwarfism, Pituitary, 38 studies
- Turner Syndrome, 10 studies
- Dwarfism, 6 studies
- Growth Disorders, 4 studies
- Genetic Diseases, Inborn, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.